Evaxion (EVAX) Stock Overview
A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EVAX Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Evaxion A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.21 |
| 52 Week High | US$12.15 |
| 52 Week Low | US$2.52 |
| Beta | 0.25 |
| 1 Month Change | 5.97% |
| 3 Month Change | -18.09% |
| 1 Year Change | 12.27% |
| 3 Year Change | -93.58% |
| 5 Year Change | -98.82% |
| Change since IPO | -99.35% |
Recent News & Updates
EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential
Analysts have adjusted their price target on Evaxion from $19.75 to $16.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Evaxion Evaxion plans to present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal, with the findings intended to guide final antigen selection for a broadly protective CMV vaccine candidate (source: recent news report).
EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential
Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.Recent updates
EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential
Analysts have adjusted their price target on Evaxion from $19.75 to $16.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Evaxion Evaxion plans to present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal, with the findings intended to guide final antigen selection for a broadly protective CMV vaccine candidate (source: recent news report).EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential
Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments). EVAX aims for at least 2 new deals in 2025 and is in the meantime further developing its AI platform to stay ahead of competition. Read the full article on Seeking AlphaEvaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, and has raised enough funding to last through 2024. Evaxion's AI models, including EDEN, RAVEN, PIONEER, ObsERV, and AI-DEEP, show promise in identifying protective antigens, designing effective and safe personalized cancer vaccines and predicting which patients will respond. Big pharma interest, pending catalysts in 2024, impressive proof-of-concept preclinical and clinical data are compelling enough for me for a small speculative position. However, the risk of considerably more dilutive funding as well as the very early stage of the pipeline make me give a "Hold" recommendation. Read the full article on Seeking AlphaEvaxion Biotech names Per Norlén as CEO
Evaxion Biotech (EVAX) said Wednesday Per Norlén joined the firm as CEO on Monday. Norlén is a physician and associate professor with over 20 years in the biotech sector, of which the last decade has been in executive leadership roles.Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Evaxion Biotech (EVAX) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck (NYSE:MRK) which is supplying the trial with its blockbuster drug Keytruda, the Danish company said in a Sept. 21 press release. Patients will receive standard of care treatment along with Keytruda in combination with EVX-01. Evaxion added that it is responsible for conducting the trial. The company expects interim topline data in H2 2023. EVAX +11.27% to $2.27 premarket Sept. 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Evaxion Biotech ADS press release (EVAX): Q2 GAAP EPS of -$0.20 beats by $0.10. As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing facilities, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.Evaxion Biotech announces new CEO as Lars Wegner resigns
Evaxion Biotech (EVAX) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development. Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indicationShareholder Returns
| EVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.2% | 4.5% | 1.0% |
| 1Y | 12.3% | 38.3% | 18.4% |
Return vs Industry: EVAX underperformed the US Biotechs industry which returned 38.3% over the past year.
Return vs Market: EVAX underperformed the US Market which returned 18.4% over the past year.
Price Volatility
| EVAX volatility | |
|---|---|
| EVAX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EVAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EVAX's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 46 | Helen Tayton-Martin | evaxion.ai |
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus.
Evaxion A/S Fundamentals Summary
| EVAX fundamental statistics | |
|---|---|
| Market cap | US$25.60m |
| Earnings (TTM) | -US$9.76m |
| Revenue (TTM) | US$7.53m |
Is EVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVAX income statement (TTM) | |
|---|---|
| Revenue | US$7.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.53m |
| Other Expenses | US$17.28m |
| Earnings | -US$9.76m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -129.60% |
| Debt/Equity Ratio | 0% |
How did EVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/13 23:39 |
| End of Day Share Price | 2026/08/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evaxion A/S is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |